Zobrazeno 1 - 10
of 121
pro vyhledávání: '"Debanjali Mitra"'
Autor:
Jeanna Wallenta Law, Debanjali Mitra, Henry G. Kaplan, Tamuno Alfred, Adam M. Brufsky, Birol Emir, Haley McCracken, Xianchen Liu, Ronda G. Broome, Chenan Zhang, Caroline DiCristo, Connie Chen
Publikováno v:
Current Oncology, Vol 29, Iss 2, Pp 1047-1061 (2022)
This retrospective single-arm study assessed real-world treatment patterns and clinical outcomes in patients with hormone receptor—positive/human epidermal growth factor receptor 2—negative (HR+/HER2−) advanced/metastatic breast cancer (A/MBC)
Externí odkaz:
https://doaj.org/article/f8c89b12620c474d8fca86acf4db753d
Autor:
Jifang Zhou, Jenilee Cueto, Naomi Y. Ko, Kent F. Hoskins, Nadia A. Nabulsi, Alemseged A. Asfaw, Colin C. Hubbard, Debanjali Mitra, Gregory S. Calip, Ernest H. Law
Publikováno v:
Breast, Vol 59, Iss , Pp 367-375 (2021)
Background: Multiple independent risk factors are associated with the prognosis of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC), the most common BC subtype. This study describes U.S. po
Externí odkaz:
https://doaj.org/article/cf5114a54f47443ca2bdb0d9fac535c1
Autor:
Nadia A Nabulsi MPH, Khatija W Naing MPH, Huiwen Deng PharmD, MPH, Jenilee Cueto MPH, Alemseged A Asfaw PhD, Colin C Hubbard PhD, Jifang Zhou MD, MPH, PhD, Inyoung Lee MS, PhD, Debanjali Mitra MBA, MA, Gregory S Calip PharmD, MPH, PhD, Ernest H Law PharmD, PhD
Publikováno v:
Journal of Patient Experience, Vol 9 (2022)
This study describes health-related quality of life (HRQoL) among older Medicare beneficiaries with hormone receptor-positive (HR+) early breast cancer (eBC). Women aged ≥65 years diagnosed with stage I-III HR+ eBC between 1997 and 2014 using the S
Externí odkaz:
https://doaj.org/article/6cf80ecdd6f54a1990a0d26bf526f04e
Publikováno v:
Current Oncology, Vol 28, Iss 1, Pp 678-688 (2021)
Background: Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative
Externí odkaz:
https://doaj.org/article/e3192d9864344b80a3d721a345ae521b
Autor:
Katie Mycock, Lin Zhan, Kieran Hart, Gavin Taylor-Stokes, Gary Milligan, Christian Atkinson, Debanjali Mitra
Publikováno v:
Cancer Treatment and Research Communications, Vol 32, Iss , Pp 100573- (2022)
Background: The incidence of breast cancer is rising in Japan, particularly in postmenopausal women. The CDK 4/6 inhibitor palbociclib has demonstrated efficacy in clinical studies in patients with hormone receptor-positive (HR+), human epidermal gro
Externí odkaz:
https://doaj.org/article/800cae2bf1b44d5784aaf3fc009aefe8
Autor:
John Waller, Debanjali Mitra, Katie Mycock, Gavin Taylor-Stokes, Gary Milligan, Lin Zhan, Shrividya Iyer
Publikováno v:
Journal of Global Oncology (2019)
PURPOSE: The selective cyclin-dependent kinase 4/6 inhibitor palbociclib was approved in Argentina in 2015 for postmenopausal women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast canc
Externí odkaz:
https://doaj.org/article/94ddc26f7c2241d28432047934b4e459
Autor:
Katie Mycock, Kent A. Hanson, Gavin Taylor-Stokes, Gary Milligan, Christian Atkinson, Debanjali Mitra, Salena Preciado, Ernest H. Law
Publikováno v:
Clinical Therapeutics. 44:1588-1601
Palbociclib was the first cyclin-dependent kinase 4/6 inhibitor approved by the US Food and Drug Administration for use in combination with aromatase inhibitors (AIs) as initial endocrine-based therapy or with fulvestrant in postmenopausal women who
Autor:
Alemseged Ayele Asfaw, Debanjali Mitra, Jifang Zhou, J. Cueto, Naomi Y. Ko, Kent Hoskins, Nadia A. Nabulsi, Colin C. Hubbard, Ernest H. Law, Gregory S. Calip
Publikováno v:
The Breast : Official Journal of the European Society of Mastology
Breast, Vol 59, Iss, Pp 367-375 (2021)
Breast, Vol 59, Iss, Pp 367-375 (2021)
Background Multiple independent risk factors are associated with the prognosis of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC), the most common BC subtype. This study describes U.S. pop
Autor:
Junji Lin, Maxine D. Fisher, Lynn McRoy, Mark S. Walker, Cralen Davis, Nan Hu, Debanjali Mitra
Publikováno v:
Future Oncology. 17:1001-1011
Background: Limited studies have evaluated palbociclib-based therapy use in patients with advanced/metastatic breast cancer in the real world. This retrospective study used medical records from US community oncology practices to address the gap. Mate
Publikováno v:
Cancer Research. 81:PS7-59
BACKGROUND: Corrected QT (QTc) prolongation is a cardiac condition that may increase the risk of ventricular arrhythmias, including Torsades de Pointes (TdP), and cardiac-related death. QTc prolongation is a notable concern in oncology as drug-induce